GEN Exclusives

More »

Sidebars

More »
Jan 15, 2009 (Vol. 29, No. 2)

BD Biosciences Expands Capabilities in Cell Culture Media

  • While BD Biosciences works toward completing construction of its recently announced animal-free/antibiotic-free (AF2) cell culture media production facility in Miami by the end of the year, the company’s new pilot lab is nearing completion.

    The pilot plant will focus on the production of cell culture media samples representative of the new commercial-scale AF2 facility, according to company officials. Custom blends of basal cell culture media and supplements are available currently via the BD Autonutrient™ media design service and its custom product development program, they add.

    Once the Miami facility begins operations, “BD Biosciences will fully serve the culture media needs of bioprocessors working with mammalian, microbial, or stem cell lines,” notes Tom Isett, vp, BD Biosciences–Advanced Bioprocessing.

    Originally designed and built for the manufacture of pharmaceuticals, the 90,000-square foot Miami plant is currently being outfitted with modern cell culture media milling, blending, and sterile liquid filling equipment.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?